---
schema_version: "secwatch.filing_event.v1"
accession: "0000885725-24-000007"
form_type: "8-K"
ticker: "BSX"
cik: "0000885725"
company_name: "BOSTON SCIENTIFIC CORP"
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:47:40.161743+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Boston Scientific to acquire Axonics for $71.00 per share in cash

## Summary
- Each Axonics share will be converted into $71.00 in cash, without interest.
- Termination fee of $75M payable by Axonics for superior proposal; $140M payable by Boston Scientific if antitrust fails after Axonics stockholder approval.
- Transaction subject to Axonics stockholder approval, HSR waiting period, and other regulatory consents.
- Axonics board unanimously recommends adoption of the merger agreement.
- Customary no-shop clause with fiduciary out allows Axonics to consider superior proposals.

## SEC filing metadata
- accession: 0000885725-24-000007
- form_type: 8-K
- ticker: BSX
- cik: 0000885725
- company_name: BOSTON SCIENTIFIC CORP
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/885725/000088572524000007/0000885725-24-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/885725/000088572524000007/bsx-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000885725-24-000007
- JSON: https://secwatch.observer/filing/0000885725-24-000007.json
- Plain text: https://secwatch.observer/filing/0000885725-24-000007.txt

## Key facts
- Material Agreements
  BOSTON SCIENTIFIC CORP entered into Agreement and Plan of Merger with Axonics, Inc. valued at Merger consideration of $71.00 per share in cash (effective 2024-01-08).
  - Action: entry
  - Agreement: merger
  - Counterparty: Axonics, Inc.
  - Value: Merger consideration of $71.00 per share in cash
  - Effective: 2024-01-08
  source text: On January 8, 2024, Boston Scientific Corporation, a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Sadie Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ Merger Sub ”), and Axonics, Inc., a Delaware corporation (“ Axonics ”), providing for the merger of Merger Sub with and into Axonics (the “ Merger ”), with Axonics surviving the Merger as a wholly owned subsidiary of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/885725/000088572524000007/0000885725-24-000007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.